CANF Stock Analysis: Buy, Sell, or Hold?
CANF - Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares
$3.30
-0.03 (-0.90%)
▼
5d:
-7.82%
30d:
+3.45%
90d:
-2.94%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Apr 13, 2026
0d
Get Alerted When CANF Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
ℹ️ NEUTRAL: CANF is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
ℹ️ NEUTRAL: CANF is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CANF is currently trading at $3.30, which is considered fair relative to its 30-day fair value range of $3.20 to $3.44.
Technical Outlook: Technically, CANF is showing sideways momentum. The price is currently testing key support at $3.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CANF scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.00 (+140.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CANF is showing sideways momentum. The price is currently testing key support at $3.24. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: CANF scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.00 (+140.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.20 -
$3.44
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (31/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 140.2% below Wall St target ($8.00)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.20 -
$3.44
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.24
Resistance Level
$3.58
Current Trend
Sideways
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-12.33
Wall Street Target
$8.00
(+140.2%)
Revenue Growth (YoY)
-43.3%
Share & Embed Analysis
Last updated: August 24, 2026 2:07 PM ET
Data refreshes hourly during market hours. Next update: 3:07 PM
Data refreshes hourly during market hours. Next update: 3:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CANF showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 46 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 45 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 68 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 51 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 32 SELL |
